查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1671092

全球重症肌無力市場：市場規模、佔有率、趨勢、產業分析（依治療類型、最終用途和地區）、未來預測（2025-2034）

Global Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type, End Use, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，重症肌無力疾病市場預計到2034年將達到 61.9億美元。本報告深入了解了當前的市場動態，並對未來的市場成長進行了分析。

重症肌無力（MG）是一種慢性自體免疫疾病，導致骨骼肌無力，尤其是控制眼球、臉部肌肉和四肢自主運動的骨骼肌無力。當人體免疫系統產生抗體，干擾神經細胞和肌肉細胞之間的通訊，阻止訊號的正常傳輸時，就會發生這種疾病。

重症肌無力疾病市場受到多種因素的推動，包括全球盛行率的增加、診斷技術的進步以及對更有效治療方案的需求不斷成長。單株抗體和免疫療法等生物製劑的開發和批准為患者提供了治療嚴重重症肌無力的新方法。

此外，根據基因和分子特徵制定治療方案的個人化醫療趨勢也備受關注。重症肌無力疾病市場的成長也得益於患者意識的提高、臨床試驗的擴大以及醫療保健機會的改善，尤其是在亞太地區等新興市場。機會包括滿足難以治療的患者的需求、提高醫療費用的可負擔性以及擴大獲得先進療法的機會。總體而言，隨著更有效、更容易取得的治療方案不斷湧現，市場預計將穩定成長。

重症肌無力疾病市場：概論

膽鹼酯酶抑制劑在重症肌無力市場中佔據主導地位，是大多數輕度至中度症狀患者的主要治療方法。然而，由於對重症病例的晚期治療的需求不斷增加，包括 IVIG 和血漿置換在內的快速免疫治療領域正顯示出最快的成長。

在重症肌無力疾病市場中，醫院佔據最大的市場佔有率，因為它們提供從急性發作到重症的綜合治療。然而，由於越來越多的人轉向門診護理以及獲得專科護理的機會增加，診所部門經歷最快的成長。

由於先進的醫療基礎設施、高度的認知度和龐大的患者數量，北美在重症肌無力市場中佔據主導地位。然而，由於醫療保健管道的擴大、診斷能力的提高以及創新療法的採用不斷增加，亞太地區是成長最快的市場。

目錄

第1章 簡介

第2章 執行摘要

第3章 分析方法

第4章 重症肌無力疾病市場洞察

  • 市場概況
  • 重症肌無力疾病的市場動態
    • 驅動因素和機會
      • 越來越重視標靶治療
      • 免疫療法的進展
    • 阻礙因素和挑戰
      • 存活率低
  • PESTLE 分析
  • 重症肌無力疾病市場的趨勢
  • 價值鏈分析
  • COVID-19 影響分析

第5章 全球重症肌無力疾病市場（依治療類型）

  • 主要調查結果
  • 簡介
  • 胸腺切除術
  • 膽鹼酯酶抑制劑
  • 快速免疫療法

第6章 全球重症肌無力疾病市場（依最終用途）

  • 主要調查結果
  • 簡介
  • 科學研究
  • 藥物與疫苗的研究與開發
  • 克隆實驗
  • 其他

第7章 全球重症肌無力疾病市場（依地區）

  • 主要調查結果
  • 簡介
    • 依地區對重症肌無力疾病市場的評估（2020-2034年）
  • 北美洲
    • 北美：依治療類型（2020-2034年）
    • 北美：依最終用途（2020-2034年）
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲：依治療類型（2020-2034年）
    • 歐洲：依最終用途（2020-2034年）
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲國家
  • 亞太地區
    • 亞太地區：依治療類型（2020-2034年）
    • 亞太地區：依最終用途（2020-2034年）
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 中東和非洲
    • 中東和非洲：依治療類型（2020-2034年）
    • 中東和非洲：依最終用途（2020-2034年）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲地區
  • 拉丁美洲
    • 拉丁美洲：依治療類型（2020-2034年）
    • 拉丁美洲：依最終用途（2020-2034年）
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家

第8章 競爭格局

  • 擴張與收購分析
    • 擴張
    • 收購
  • 夥伴關係/協作/協議/公開

第9章 公司簡介

  • Alexion Pharmaceuticals（AstraZeneca）
  • Mitsubishi Tanabe Pharma
  • Bristol Myers Squibb
  • Grifols
  • Baxter International
  • CSL Behring
  • UCB
  • Prothena Biosciences
  • Argenx
  • Sanofi
  • Amgen
  • AbbVie
  • Pfizer
  • Roche
  • Novartis
Product Code: PM1546

The myasthenia gravis disease market size is expected to reach USD 6.19 billion by 2034, according to a new study by Polaris Market Research. The report "Myasthenia Gravis Disease Market Size, Share, Trends, Industry Analysis Report: By Treatment Type (Thymectomy, Cholinesterase Inhibitors, and Rapid Immunotherapies), End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Myasthenia Gravis (MG) is a chronic autoimmune disorder that causes weakness in the skeletal muscles, particularly those responsible for controlling voluntary movements like eye muscles, facial muscles, and limbs. The condition occurs when the body's immune system produces antibodies that interfere with the communication between nerve cells and muscle cells, preventing the normal transmission of signals.

The myasthenia gravis disease market is driven by several factors, including the increasing global prevalence of the condition, advancements in diagnostic techniques, and the growing demand for more effective treatment options. The development and approval of biologic therapies, such as monoclonal antibodies and immunotherapies, are offering patients new ways to manage severe forms of the disease.

Additionally, the trend toward personalized medicine, which tailors treatments based on genetic and molecular profiles, is gaining traction. The myasthenia gravis disease market growth is also supported by rising patient awareness, the expansion of clinical trials, and improving healthcare access, particularly in emerging markets such as Asia Pacific. Opportunities lie in addressing the needs of refractory patients, improving treatment affordability, and expanding access to advanced therapies. Overall, the market is poised for steady growth as more effective and accessible treatment options continue to emerge.

Myasthenia Gravis Disease Market Report Highlights

Cholinesterase inhibitors dominate the myasthenia gravis market, serving as the primary treatment for most patients with mild to moderate symptoms. However, the segment of rapid immunotherapies, including IVIG and plasmapheresis, is registering the fastest growth due to increasing demand for advanced therapies in severe cases.

Hospitals hold the largest myasthenia gravis disease market share in the myasthenia gravis treatment market, as they provide comprehensive care for both acute exacerbations and severe MG cases. The clinic segment, however, is experiencing the fastest growth, driven by the increasing shift towards outpatient care and improved accessibility to specialized treatments.

North America dominates the myasthenia gravis market, owing to its advanced healthcare infrastructure, high awareness, and significant patient population. However, Asia Pacific is the fastest growing market, driven by expanding healthcare access, improving diagnostic capabilities, and increasing adoption of innovative therapies.

Polaris Market Research has segmented the myasthenia gravis disease market report based on treatment type, end-use, and region:

By Treatment Type Outlook (Revenue-USD Billion, 2020 - 2034)

  • Thymectomy
  • Cholinesterase Inhibitors
  • Rapid Immunotherapies

By End Use Outlook (Revenue-USD Billion, 2020 - 2034)

  • Hospitals
  • Clinics

By Regional Outlook (Revenue-USD Billion, 2020 - 2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Myasthenia Gravis Disease Market Insights

  • 4.1. Myasthenia Gravis Disease Market - Market Snapshot
  • 4.2. Myasthenia Gravis Disease Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increased Focus on Targeted Therapies
      • 4.2.1.2. Advancements in Immunotherapy
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Low Survival Rates
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Myasthenia Gravis Disease Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Myasthenia Gravis Disease Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • 5.3. Thymectomy
    • 5.3.1. Global Myasthenia Gravis Disease Market, by Thymectomy, by Region, 2020-2034 (USD Billion)
  • 5.4. Cholinesterase Inhibitors
    • 5.4.1. Global Myasthenia Gravis Disease Market, by Cholinesterase Inhibitors, by Region, 2020-2034 (USD Billion)
  • 5.5. Rapid Immunotherapies
    • 5.5.1. Global Myasthenia Gravis Disease Market, by Rapid Immunotherapies, by Region, 2020-2034 (USD Billion)

6. Global Myasthenia Gravis Disease Market, by End-use

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 6.3. Scientific Research
    • 6.3.1. Global Myasthenia Gravis Disease Market, by Scientific Research, by Region, 2020-2034 (USD Billion)
  • 6.4. Medicine and Vaccine R&D
    • 6.4.1. Global Myasthenia Gravis Disease Market, by Medicine and Vaccine R&D, by Region, 2020-2034 (USD Billion)
  • 6.5. Cloning Experiment
    • 6.5.1. Global Myasthenia Gravis Disease Market, by Cloning Experiment, by Region, 2020-2034 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Myasthenia Gravis Disease Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Myasthenia Gravis Disease Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Myasthenia Gravis Disease Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 7.3. Myasthenia Gravis Disease Market - North America
    • 7.3.1. North America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.3.2. North America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.3.3. Myasthenia Gravis Disease Market - U.S.
      • 7.3.3.1. U.S.: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.3.3.2. U.S.: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.3.4. Myasthenia Gravis Disease Market - Canada
      • 7.3.4.1. Canada: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.3.4.2. Canada: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.4. Myasthenia Gravis Disease Market - Europe
    • 7.4.1. Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.4.2. Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.3. Myasthenia Gravis Disease Market - UK
      • 7.4.3.1. UK: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.3.2. UK: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.4. Myasthenia Gravis Disease Market - France
      • 7.4.4.1. France: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.4.2. France: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.5. Myasthenia Gravis Disease Market - Germany
      • 7.4.5.1. Germany: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.5.2. Germany: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.6. Myasthenia Gravis Disease Market - Italy
      • 7.4.6.1. Italy: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.6.2. Italy: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.7. Myasthenia Gravis Disease Market - Spain
      • 7.4.7.1. Spain: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.7.2. Spain: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.8. Myasthenia Gravis Disease Market - Netherlands
      • 7.4.8.1. Netherlands: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.8.2. Netherlands: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.9. Myasthenia Gravis Disease Market - Russia
      • 7.4.9.1. Russia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.9.2. Russia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.4.10. Myasthenia Gravis Disease Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.4.10.2. Rest of Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.5. Myasthenia Gravis Disease Market - Asia Pacific
    • 7.5.1. Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.5.2. Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.3. Myasthenia Gravis Disease Market - China
      • 7.5.3.1. China: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.3.2. China: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.4. Myasthenia Gravis Disease Market - India
      • 7.5.4.1. India: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.4.2. India: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.5. Myasthenia Gravis Disease Market - Malaysia
      • 7.5.5.1. Malaysia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.5.2. Malaysia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.6. Myasthenia Gravis Disease Market - Japan
      • 7.5.6.1. Japan: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.6.2. Japan: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.7. Myasthenia Gravis Disease Market - Indonesia
      • 7.5.7.1. Indonesia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.7.2. Indonesia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.8. Myasthenia Gravis Disease Market - South Korea
      • 7.5.8.1. South Korea: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.8.2. South Korea: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.9. Myasthenia Gravis Disease Market - Australia
      • 7.5.9.1. Australia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.9.2. Australia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.5.10. Myasthenia Gravis Disease Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.5.10.2. Rest of Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.6. Myasthenia Gravis Disease Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.6.2. Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.3. Myasthenia Gravis Disease Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.4. Myasthenia Gravis Disease Market - UAE
      • 7.6.4.1. UAE: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.4.2. UAE: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.5. Myasthenia Gravis Disease Market - Israel
      • 7.6.5.1. Israel: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.5.2. Israel: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.6. Myasthenia Gravis Disease Market - South Africa
      • 7.6.6.1. South Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.6.2. South Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.6.7. Myasthenia Gravis Disease Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.6.7.2. Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • 7.7. Myasthenia Gravis Disease Market - Latin America
    • 7.7.1. Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
    • 7.7.2. Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.3. Myasthenia Gravis Disease Market - Mexico
      • 7.7.3.1. Mexico: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.3.2. Mexico: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.4. Myasthenia Gravis Disease Market - Brazil
      • 7.7.4.1. Brazil: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.4.2. Brazil: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.5. Myasthenia Gravis Disease Market - Argentina
      • 7.7.5.1. Argentina: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.5.2. Argentina: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
    • 7.7.6. Myasthenia Gravis Disease Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
      • 7.7.6.2. Rest of Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Alexion Pharmaceuticals (AstraZeneca)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Mitsubishi Tanabe Pharma
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bristol Myers Squibb
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Grifols
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Baxter International
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. CSL Behring
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. UCB
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Prothena Biosciences
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Argenx
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Sanofi
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Amgen
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. AbbVie
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Pfizer
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Roche
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Novartis
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development

List of Tables:

  • Table 1 Global Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 2 Global Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 3 North America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 4 North America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 5 U.S.: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 6 U.S.: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 7 Canada: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 8 Canada: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 9 Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 10 Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 11 UK: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 12 UK: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 13 France: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 14 France: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 15 Germany: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 16 Germany: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 17 Italy: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 18 Italy: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 19 Spain: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 20 Spain: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 21 Netherlands: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 22 Netherlands: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 23 Russia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 24 Russia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 25 Rest of Europe: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 26 Rest of Europe: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 27 Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 28 Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 29 China: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 30 China: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 31 India: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 32 India: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 33 Malaysia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 34 Malaysia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 35 Japan: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 36 Japan: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 37 Indonesia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 38 Indonesia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 39 South Korea: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 40 South Korea: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 41 Australia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 42 Australia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 43 Rest of Asia Pacific: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 44 Rest of Asia Pacific: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 45 Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 46 Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 47 Saudi Arabia: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 48 Saudi Arabia: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 49 UAE: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 50 UAE: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 51 Israel: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 52 Israel: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 53 South Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 54 South Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 55 Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 56 Rest of Middle East & Africa: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 57 Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 58 Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 59 Mexico: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 60 Mexico: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 61 Brazil: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 62 Brazil: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 63 Argentina: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 64 Argentina: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)
  • Table 65 Rest of Latin America: Myasthenia Gravis Disease Market, by Treatment Type, 2020-2034 (USD Billion)
  • Table 66 Rest of Latin America: Myasthenia Gravis Disease Market, by End-use, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Myasthenia Gravis Disease Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Treatment Type
  • Figure 7. Global Myasthenia Gravis Disease Market, by Treatment Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by End-use
  • Figure 9. Global Myasthenia Gravis Disease Market, by End-use, 2024 & 2034 (USD Billion)